Disease · MONDO_0005265
inflammatory bowel disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. inflammatory bowel disease. Diseases, record MONDO_0005265. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005265
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Bowel Diseases, Inflammatory, IBD, INFLAMM BOWEL DIS, Inflammatory Bowel Diseases, autoimmune bowel disorder
- Open Targets
Drugs103
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMINOSALICYLIC ACID | CHEMBL1169 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| BALSALAZIDE | CHEMBL1201346 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| SULESOMAB | CHEMBL2108809 | Antibody | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| VEDOLIZUMAB | CHEMBL1743087 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| FERRIC CARBOXYMALTOSE | CHEMBL2108597 | Phase 3 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets | |
| IRON ISOMALTOSIDE 1000 | CHEMBL4298046 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets | |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FERROUS FUMARATE | CHEMBL1200640 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IRON SUCROSE | CHEMBL1200823 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 103
See all 103 drugsTargets89
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 10 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 3 | Arachidonate 5-lipoxygenase inhibitor | Approval | https://conductscience.org/library/genes/240 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| MAPK14 | Mitogen-activated protein kinase 14 | 3 | MAP kinase p38 alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/1432 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 3 | Peroxisome proliferator-activated receptor gamma agonist | Approval | https://conductscience.org/library/genes/5468 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
1 to 10 of 89
See all 89 targetsTrials79
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02680756 | Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD | Phase 3 | 250 | 2020-02-24 | Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease | FERRIC CARBOXYMALTOSE, FERRIC MALTOL | Its record names the disease | ClinicalTrials.gov |
| NCT03201445 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease | Phase 2 | 139 | 2023-12-06 | Inflammatory Bowel Disease | FILGOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01559675 | Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery | Not applicable | 121 | 2014-08-29 | Orthostatic Hypotension, Hemodynamic Instability, Fever, Hypothermia | HYDROCORTISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00325078 | Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease | Phase 1/2 | 40 | 2015-12-29 | Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD) | ADALIMUMAB, INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01999400 | Correlation of Mesalamine Pharmacokinetics With Local Availability | Not applicable | 30 | 2017-05-15 | Local Drug Concentration in Gastrointestinal Tract | MESALAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT02413047 | Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator | Not applicable | 3 | 2019-11-04 | Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease | AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT03139032 | Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations | Phase 2 | 1 | 2020-12-31 | Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations | ETRASIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT03760562 | The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases | 111,804 | Hypertension | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT03375424 | Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany | 2,500 | Inflammatory Bowel Diseases, Treatment | VEDOLIZUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT00724529 | Post Marketing Surveillance of Remicade | 938 | Crohn's Disease, Ankylosing Spondylitis | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 79
See all 79 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oral Ferric Iron Compound vs Intravenous Iron: Number of Patients With Treatment-emergent Adverse Events (AEs) | 75 of 127 | 43 of 120 | 247 | NCT02680756 | Trial comparisons |
| Oral Ferric Iron Compound vs Intravenous Iron: deaths from any cause | 1 of 127 | 0 of 120 | 247 | NCT02680756 | Trial comparisons |
| Oral Ferric Iron Compound vs Intravenous Iron: Number of Patients With Treatment-emergent Serious Adverse Events (SAEs) | 9 of 127 | 3 of 120 | 247 | NCT02680756 | Trial comparisons |
| Oral Ferric Iron Compound vs Intravenous Iron: serious adverse events | 12 of 127 | 4 of 120 | 247 | NCT02680756 | Trial comparisons |
| Filgotinib vs Placebo: deaths from any cause | 0 of 92 | 0 of 70 | 162 | NCT03201445 | Trial comparisons |
| Filgotinib vs Placebo: serious adverse events | 3 of 92 | 2 of 70 | 162 | NCT03201445 | Trial comparisons |
| High Dose Steroid vs Low Dose Steroid: Orthostatic Hypotension | 2 of 43 | 2 of 49 | 92 | NCT01559675 | Trial comparisons |
| High Dose Steroid vs Low Dose Steroid: serious adverse events | 0 of 43 | 0 of 49 | 92 | NCT01559675 | Trial comparisons |
Papers from its trials54
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005265
GET https://conductscience.org/api/diseases/v1/MONDO_0005265/drugs?page=2